New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePinealon vs Survodutide

Pinealon vs Survodutide

Side-by-side comparison of key properties, dosing, and research.

Cognitive EnhancementAnti-Aging & Longevity
Pinealon
GLP-1 / Weight Loss Agonists
Survodutide
Summary
Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed by the St. Petersburg Institute of Bioregulation, designed to penetrate the blood-brain barrier and exert neuroprotective, neurogenic, and anti-aging effects by regulating pineal gland and brain cell function.
Survodutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 trials demonstrated up to 18.7% body weight reduction at 46 weeks, among the highest reported for a dual agonist. It is being studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis), where the glucagon component drives hepatic fat clearance.
Half-Life
Short (peptides rapidly degraded), but epigenetic/gene regulatory effects persist
~7 days
Admin Route
SubQ, Oral, Intranasal
SubQ
Research
Typical Dose
5–10 mg (oral) or 50–100 mcg (SC)
0.6 mg → 2.4 mg → 4.8 mg → 6 mg
Frequency
Once daily for 10 days
Once weekly
Key Benefits
  • Neuroprotection against oxidative stress and hypoxia
  • Promotes neuronal regeneration and repair
  • Improves memory and cognitive function
  • Enhances sleep quality via melatonin regulation
  • Anti-aging effects on brain cells
  • May slow cognitive decline in neurodegeneration
  • Improves cerebrovascular circulation
  • Reduces neuroinflammation
  • Up to 18.7% body weight reduction at 46 weeks (Phase 2)
  • Strong MASH activity — Phase 3 SYNCHRONIZE-NASH trials ongoing
  • Reduces hepatic fat content via glucagon receptor-driven liver oxidation
  • Once-weekly subcutaneous injection
  • Greater weight loss potential than GLP-1 monotherapy
  • Improvements in liver fibrosis markers in early data
Side Effects
  • Excellent safety profile in clinical use
  • Rare: mild drowsiness
  • Transient mild headache at initiation
  • Injection site reaction (SC)
  • Nausea (most common during titration)
  • Vomiting
  • Diarrhea
  • Decreased appetite
  • +3 more
Stacks With